TAK-079

Phase 2Small molecule

Takeda

TAK-079 is one of 152 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

151

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

Multiple MyelomaActive, not recruiting

LupusActive, not recruiting

Myasthenia GravisActive, not recruiting

Immune ThrombocytopeniaActive, not recruiting

Systemic Lupus ErythematosusPhase 1

Active, not recruiting

Multiple MyelomaPhase 1

Active, not recruiting

LupusPhase 2

Active, not recruiting

Myasthenia GravisPhase 2

Active, not recruiting

Immune ThrombocytopeniaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1135 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Ninlaro

Takeda

Preclinical

18 2

TAK-079

Takeda

Phase 2

1 3

Prolia

Amgen

Preclinical

5 4

Eliquis

Bristol-Myers Squibb

Preclinical

3 5

Adriamycin

GGynecologic Oncology Group

Preclinical

9 6

Nolvadex

AstraZeneca

Preclinical

1 7

Oncovin

EEastern Cooperative Oncology Group

Preclinical

8 8

Intron a

Abecma

4 10

Oblimersen Sodium

NNational Cancer Institute (NCI)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Immune Thrombocytopenia1 trial

A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia

Completed· Takeda logo

Takeda·Phase 2·NCT04278924·41 enrolled

Multiple Myeloma1 trial

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

Active, not recruiting· Takeda logo

Takeda·Phase 1·NCT03984097·50 enrolled

Phase 11 trial

A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of TAK-079 in Healthy Participants

Completed· Takeda logo

Takeda·Phase 1·NCT02219256·74 enrolled

Systemic Lupus Erythematosus1 trial

A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)

Completed· Takeda logo

Takeda·Phase 1·NCT03724916·23 enrolled

Myasthenia Gravis1 trial

A Study of TAK-079 in People With Generalized Myasthenia Gravis

Completed· Takeda logo

Takeda·Phase 2·NCT04159805·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for TAK-079. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TAK-079 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TAK-079. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Takeda

TAK-079

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Immune Thrombocytopenia1 trial

Multiple Myeloma1 trial

Phase 11 trial

Systemic Lupus Erythematosus1 trial

Myasthenia Gravis1 trial

References

Drug Info

Quick Facts

Related News